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The Polo-related kinase Cdc5 activates and is destroyed by the
mitotic cyclin destruction machinery in S. cerevisiae
Julia F. Charles, Sue L. Jaspersen, Rachel L. Tinker-Kulberg, Lena Hwang, Alex
Szidon, and David O. Morgan
Background: Following chromosome segregation in anaphase, ubiquitin-
dependent degradation of mitotic cyclins contributes to the exit from mitosis. A
key step in this process is catalyzed by a ubiquitin–protein ligase known as the
anaphase-promoting complex (APC), the regulation of which is poorly understood.
The Polo-related protein kinase Cdc5 in Saccharomyces cerevisiae might encode
a regulator of the APC, because cdc5 mutant cells arrest with a late mitotic
phenotype similar to that observed in cells with defective cyclin destruction.
Results: We investigated the role of Cdc5 in the regulation of mitotic cyclin
degradation. In cdc5-1 mutant cells, we observed a defect in the destruction of
cyclins and a reduction in the cyclin–ubiquitin ligase activity of the APC.
Overexpression of CDC5 resulted in increased APC activity and mitotic cyclin
destruction in asynchronous cells or in cells arrested in metaphase. CDC5
mutation or overexpression did not affect the degradation of the APC substrate
Pds1, which is normally degraded at the metaphase-to-anaphase transition.
Cyclin-specific APC activity in cells overexpressing CDC5 was reduced in the
absence of the APC regulatory proteins Hct1 and Cdc20. In G1, Cdc5 itself
was degraded by an APC-dependent and Hct1-dependent mechanism.
Conclusions: We conclude that Cdc5 is a positive regulator of cyclin-specific
APC activity in late mitosis. Degradation of Cdc5 in G1 might provide a
feedback mechanism by which the APC destroys its activator at the onset of
the next cell cycle. 
Background
The events of mitosis are governed by oscillations in the
activity of cyclin-dependent protein kinases (Cdks), the
activity of which requires association with mitotic cyclins
[1–4]. Activation of mitotic Cdk–cyclin complexes, such as
the Cdc2–cyclin B complex of vertebrates or the
Cdc28–Clb complex of Saccharomyces cerevisiae, triggers the
sequence of events that lead to chromosome segregation.
Inactivation of mitotic Cdks is then required to allow pro-
gression from anaphase to G1. The major mechanism of
Cdk inactivation in late mitosis is ubiquitin-dependent
cyclin proteolysis by the 26S proteasome (reviewed in
[5–7]). Overexpression of non-degradable mutant cyclin
proteins results in a late anaphase arrest in a wide range of
eukaryotes, suggesting that Cdk inactivation by cyclin
degradation is a highly conserved mechanism controlling
the exit from mitosis [8–14]. Complete cyclin destruction
is not absolutely required for mitotic exit, however: addi-
tional Cdk inactivation mechanisms might contribute to
mitotic exit under some conditions [15–19]. 
The ubiquitination of mitotic cyclins is a key regulatory
step in their destruction. Cyclin ubiquitination, like that
of other proteins, begins with the transfer of ubiquitin
from the ubiquitin-activating enzyme (E1) to one of a
family of ubiquitin-conjugating enzymes (E2) [20–22].
Ubiquitin is then transferred from E2 to the substrate by a
ubiquitin–protein ligase (E3). For mitotic cyclins, the E3
is a large, multimeric enzyme known as the cyclosome or
anaphase-promoting complex (APC) [21,23–27], the activ-
ity of which is low during interphase and high in late
mitosis and G1 [21,23,28–31]. The mechanisms governing
APC activity during the cell cycle are not well understood.
In extracts of clam and frog cells, the mitotic
Cdc2–cyclin B complex itself promotes activation of the
APC [23,29,32]. On the other hand, in S. cerevisiae there is
genetic evidence that APC-dependent cyclin destruction
is inhibited by Cdc28–cyclin activity [33]. The cyclic
AMP-dependent protein kinase might also contribute to
regulation of the APC [34,35].
The APC is required not only for cyclin destruction but
for the destruction of additional proteins, such as Pds1 and
Cut2, that inhibit chromosome separation [36,37]. As a
result, general defects in APC activity cause a metaphase
arrest with unseparated chromosomes [10,24], not the late
anaphase arrest that results from overexpression of non-
degradable cyclins. Recent genetic evidence suggests that
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the targeting of different substrates to the APC might be
controlled by members of the Cdc20 protein family
[17,18,38]. In S. cerevisiae, Cdc20 is required primarily for
APC-mediated destruction of Pds1, whereas the related
protein Hct1/Cdh1 is required for destruction of mitotic
cyclins (for example, Clb2) and Ase1 [17,18]. Cdc20 might
serve as a target for regulation in cells that are blocked in
metaphase due to defects in spindle assembly. These cells
arrest with high levels of Clb2, and recent evidence sug-
gests that this checkpoint arrest is dependent on an
inhibitory interaction between checkpoint signaling pro-
teins and Cdc20 [39,40]. 
Whereas defects in APC subunits or Cdc20 cause a
metaphase arrest before chromosome segregation, muta-
tions in a distinct group of genes cause a late-anaphase
arrest similar to that seen in cells overexpressing non-
degradable mutant cyclin [41]. These genes encode
potential regulatory proteins related to protein kinases
(Cdc5, Cdc15, Dbf2), phosphatases (Cdc14), and GTPases
(Tem1) [42–46], and an intriguing possibility is that these
proteins are components of regulatory networks that
promote Cdc28 inactivation by cyclin-specific APC activ-
ity or other inhibitory mechanisms. 
Among the genes that function late in mitosis, CDC5 is of
particular interest because it encodes a member of the
highly conserved family of Polo-related protein kinases
[42]; the members of this family have been implicated in
the control of mitosis in a wide range of eukaryotes [47]. In
Drosophila and human cells, the related kinases Polo and
Plk1, respectively, are required for normal maturation of
centrosomes and the mitotic spindle [48,49]. The Polo-
related kinases Plx1 in Xenopus [50] and Prk1 in human
cells [51] might promote mitotic entry by activating the
phosphatase Cdc25C, a key activator of Cdc2–cyclin B1.
The Plo1 protein of Schizosaccharomyces pombe is required
for both mitotic entry and exit: mutations in plo1+ result in
spindle defects as well as a failure to undergo septum for-
mation and cytokinesis [52]. Unlike Polo-related kinases of
other eukaryotes, the Cdc5 protein of S. cerevisiae does not
appear to be required for mitotic entry: the late mitotic
arrest of cdc5 mutants suggests that mitosis and chromo-
some separation occur normally in the absence of CDC5
function, but that progression beyond anaphase is blocked. 
We tested the hypothesis that the late mitotic arrest of
cdc5 mutants reflects a requirement for Cdc5 in the inacti-
vation of Cdc28 following chromosome segregation. We
found that the cyclin-specific ubiquitination activity of
the APC is reduced in the cdc5-1 mutant and increased in
cells overexpressing CDC5, suggesting that Cdc5 is a rate-
limiting determinant of APC activity and cyclin destruc-
tion. Moreover, Cdc5 itself is degraded in G1 by an
APC-dependent and Hct1-dependent pathway. By
destroying its activator at the end of mitosis, the APC
might set the stage for its own inactivation at the end of
the next G1 phase.
Results
Mutants in CDC5 are defective in destruction of Clb2
The arrest phenotype of cdc5-1 is reminiscent of cells
overexpressing non-degradable Clb2, raising the possibil-
ity that this mutant is defective in cyclin destruction. Con-
sistent with this possibility, we found that Clb2 levels
were elevated in the cdc5-1 mutant at the permissive tem-
perature and remained high at the restrictive temperature
(Figure 1a). We also analyzed levels of Pds1, an APC sub-
strate normally degraded at the metaphase-to-anaphase
transition. Pds1 levels were reduced in the cdc5-1 mutant
at the restrictive temperature, consistent with the
anaphase arrest in these mutants (Figure 1a). 
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Figure 1
The cdc5-1 mutant is specifically defective in
Clb2 proteolysis. (a) Wild-type (JC243) and
cdc5-1 (JC247) strains were shifted from 25°C
to 37°C for 3 h. Endogenous Clb2 and HA-
epitope-tagged Pds1 were analyzed by
western blotting with affinity-purified anti-Clb2
antibody and the anti-HA antibody 16B12,
respectively. Pds1 normally migrates as a
doublet. (b) Cultures of wild-type (JC95) and
cdc5-1 (JC94) strains containing a GAL
promoter-driven CLB2 construct, as well as
control strains lacking the CLB2 construct,
were serially diluted and spotted to a plate
containing 2% galactose at 23°C. (c) A cdc5-1
strain (JC34) was transformed with a multi-
copy vector (pRS426) containing SIC1,
CDC5, or no insert (control); overnight cultures
were serially diluted and spotted to YPD plates
at 23°C and 37°C.
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We also examined the effect of CLB2 overexpression on
growth of the cdc5-1 mutant (Figure 1b). Whereas the
growth of a wild-type strain was not affected by CLB2
overexpression, excess Clb2 was lethal in the cdc5-1
mutant at the permissive temperature, suggesting that
cdc5-1 mutant cells are compromised in their ability to
destroy mitotic cyclins. Furthermore, overproduction of
Sic1, an inhibitor of Cdc28–Clb kinase activity [53,54],
allowed growth of cdc5-1 cells at 37°C (Figure 1c), as
shown previously [15]. Thus, the primary defect in cdc5-1
mutants is an inability to inactivate mitotic Cdc28 activity.
APC activity is compromised in cdc5-1 mutants
To test the possibility that impaired Clb2 degradation in
the cdc5-1 mutant is due to a defect in APC-mediated
ubiquitination, we developed an assay to measure the
cyclin–ubiquitin ligase activity of the APC in vitro. We
isolated the APC from yeast extracts by immunoprecipita-
tion with antibodies against APC subunits, including
epitope-tagged Cdc16, epitope-tagged Cdc27, or endoge-
nous Cdc26. Immunoprecipitates were incubated with
excess purified yeast E1 (Uba1) and E2 (Ubc4), bovine
ubiquitin, ATP, and 125I-labeled sea urchin cyclin B
amino terminus [10,55]. Analysis of reaction products by
polyacrylamide gel electrophoresis revealed the formation
of a series of ubiquitin-conjugated substrate molecules.
Unlike previously described yeast APC assays in which
activity is measured in crude cell lysates, activity mea-
sured by our method reflects the activity that is tightly
associated with only the E3 component. Formation of
ubiquitin–cyclin conjugates required ATP and all three
ubiquitination enzymes, and activity increased linearly
with increasing amounts of APC (data not shown). Activ-
ity was absent in the APC subunit mutants cdc16-1 and
cdc23-1 (see below; data not shown).
We compared the APC activity in cdc5-1 mutants to that in
wild-type strains (Figure 2). APC from cdc5-1 cells arrested
at 37°C possessed negligible activity, suggesting that high
Clb2 levels and the late-anaphase arrest in this mutant
might be due to loss of APC activity. We also examined
cdc5-1 cells that had been arrested in G1 with mating
pheromone (α-factor) and then shifted to the non-permis-
sive temperature (Figure 2). APC activity from G1-arrested
cdc5-1 mutants at the permissive temperature was signifi-
cantly lower than that in wild-type cells. Shift to the restric-
tive temperature caused a slight additional decrease in APC
activity that was also seen in wild-type cells, suggesting that
Cdc5 is not required to maintain APC activity in G1. 
Peak Cdc5 kinase activity precedes activation of the APC in
mitosis
Cdc5 mRNA is known to peak at the G2–M phase transi-
tion [42], and Cdc5 protein levels are low in G1, rise to a
peak at G2–M, and decrease as cells enter the next G1
phase [56] (Figure 3c). The timing of Cdc5 activity in the
yeast cell cycle, and particularly the relationship between
Cdc5 activity and APC activity, are unknown. We there-
fore compared APC and Cdc5 activities in cells after
release from a G1 arrest. APC activity was high in G1
(Figure 3a), dropped dramatically as cells passed Start, and
remained low while Clb2 levels and Clb2-associated
kinase activity increased. Shortly after the peak in Clb2-
associated activity, APC activity increased abruptly,
remained high as Clb2 levels declined, and then
decreased as cells entered the next cell cycle (Figure 3).
Cdc5-associated kinase activity and protein levels
(Figure 3b,c) were undetectable in G1 cells, consistent
with our observation that Cdc5 is not required for mainte-
nance of APC activity. Cdc5 activity rose to a peak just
before the increase in APC activity, consistent with the
possibility that Cdc5 is a positive regulator of the APC.
CDC5 overexpression decreases Clb2 levels but does not
significantly affect Pds1 
If Cdc5 is a limiting regulator of cyclin proteolysis, then
increasing Cdc5 levels might decrease cyclin levels. We
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Figure 2
Cyclin–ubiquitin ligase activity of the APC is defective in cdc5-1 mutants.
Wild-type (AFS92) and cdc5-1 (JC34) strains were transformed with a
CEN–ARS plasmid carrying CDC16HA under the control of its own
promoter. Asynchronous cultures were grown to mid-log phase at 25°C
(lanes 1,3) or shifted to 37°C for 2 h (lanes 2,4). In lanes 5–8, cells were
treated with 1 µg/ml α-factor until over 90% of cells displayed G1
morphology, then grown at either 25°C (lanes 5,7) or shifted to 37°C for
1 h (lanes 6,8). Cell lysates (500µg) were prepared, and the APC was
immunoprecipitated with the anti-HA antibody 12CA5. APC activity in
immunoprecipitates was measured by the conjugation of ubiquitin to 125I-
labeled cyclin amino terminus as described in Materials and methods. A
ladder of ubiquitin-conjugated substrate is apparent above the non-
ubiquitinated substrate at the bottom of the figure. The asterisk indicates a
background band present in the non-ubiquitinated substrate. The level of
Cdc16 protein is not affected by the cdc5-1 mutation (data not shown).
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addressed this issue by testing the effects of CDC5 overex-
pression. We constructed a strain containing three inte-
grated copies of myc3–CDC5 (which complements the
cdc5-1 defect) under the control of the GAL promoter. In an
asynchronous population, induction of CDC5 expression
resulted in a dramatic drop in Clb2 levels (Figure 4). In
four separate experiments, Pds1 levels did not change sig-
nificantly after CDC5 induction. In cells treated with
hydroxyurea or nocodazole, which are arrested in S phase or
mitosis respectively with high Clb2 levels, Cdc5 overpro-
duction also triggered extensive Clb2 destruction. Once
again, Pds1 levels were not reproducibly affected. Overex-
pression of CDC5 in asynchronous cells did not significantly
affect the cell-cycle profile during the 3 hour time course of
these experiments, but continued overexpression of CDC5
resulted in growth arrest with a non-uniform terminal phe-
notype (data not shown). As CDC5 overexpression results in
decreased Clb2 in cells arrested in S phase and mitosis,
CDC5 cannot be acting merely by causing a cell-cycle block
at a stage when the APC is active. Instead, these results
clearly show that Cdc5 can regulate Clb2 levels. 
Ectopic expression of CDC5 leads to increased APC activity 
We tested the hypothesis that Cdc5 is an activator of the
APC by measuring the activity of the APC isolated from
cells overexpressing CDC5. In asynchronous cells or in
cells arrested in mitosis with nocodazole, overproduction
of Cdc5 resulted in a dramatic increase in the cyclin–ubiq-
uitin ligase activity of the APC (Figure 5a). Similar results
were obtained in cdc13-1 mutant cells, which arrest in
mitosis due to activation of the DNA-damage checkpoint.
Increases in APC activity in vitro were accompanied by
reduced Clb2 levels in vivo (Figure 5c), consistent with
the possibility that the APC activity measured in our assay
is a key determinant of cyclin levels in the cell. Further-
more, the decrease in Clb2 that accompanied CDC5 over-
expression was not observed in an APC mutant (cdc23-1),
indicating that the effects of Cdc5 on Clb2 levels are
mediated by the APC. There is evidence that Cdc28–Clb
activity inhibits Clb2 proteolysis [33], and therefore CDC5
overexpression could indirectly activate the APC by
inhibiting Clb-associated kinase activity. We eliminated
this possibility by showing that CDC5 induction did not
inhibit Clb2-associated kinase activity in cdc23-arrested
cells, which contain stable Clb2 (Figure 5d). 
CDC5 overexpression does not cause rebudding in nocoda-
zole-arrested cells (data not shown), suggesting that the
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Figure 3
Cell-cycle regulation of APC and Cdc5-dependent kinase activities. A
cdc5::CDC5HA3 cdc27::CDC27MBP strain (JC35) was synchronized in
G1 by treatment with 1 µg/ml α-factor (over 96% of cells were in G1).
Cells were released into YPD at 25°C and cell lysates were prepared
from samples taken every 15 min. The lane labeled A represents a
sample from asynchronous cells. (a) APC was immunoprecipitated
from cell extracts (200 µg) with anti-MBP (maltose-binding protein)
antibody, and cyclin–ubiquitin ligase activity was measured in vitro as
described in Materials and methods. (b) Cdc5 was
immunoprecipitated from 750 µg of cell extract with 12CA5, and
Cdc5-dependent casein kinase activity was measured as described in
Materials and methods. (c) Cdc5 was detected by western blotting
with the 12CA5 antibody. (d) Clb2 was detected by western blotting
with affinity-purified anti-Clb2 antibody. (e) Clb2-associated histone
H1 kinase activity (HH1) was measured in anti-Clb2
immunoprecipitates from 100 µg cell extract. The percentage of
budded cells in each sample is shown below the gels.
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Figure 4
Cdc5 overproduction results in decreased Clb2 levels. A strain
containing three integrated copies of GAL–myc3–CDC5 (JC251) and
a control strain lacking inducible CDC5 (JC 243) were grown in
YEP/raffinose to early log phase. Cultures were arrested either in S
phase with 10 mg/ml hydroxyurea, in mitosis with 10 µg/ml
nocodazole, or were left untreated as asynchronous cultures. Cultures
were divided, and galactose or dextrose was added to 2% final
concentration for 3 h to induce (+) or repress (–) CDC5 expression,
respectively. Clb2 and HA-epitope-tagged Pds1 were detected by
western blotting of cell extracts with anti-Clb2 and 16B12 antibodies,
respectively. In four separate experiments, no reproducible changes in
Pds1 levels were observed in cells overexpressing CDC5.
Clb2
Pds1
Asynchronous Hydroxyurea Nocodazole
GAL–CDC5+ +–
– – – – – –
– – – – –+ + + +
+ + ++ + + CDC5
induction
Current Biology
mitotic arrest is maintained. To pursue this possibility
further, we examined sister-chromatid separation in these
cells by the method described in Straight et al. [57], in
which a locus on chromosome IV is marked with a lac
operator array which can be visualized by the binding of a
green fluorescent protein (GFP)–LacI fusion protein.
CDC5 overexpression had no significant effect on sister-
chromatid separation or budding index (Figure 5e). As
sister-chromatid separation is known to require Pds1
degradation [37], these results are consistent with our
observation that Pds1 levels are not affected by CDC5
overexpression (Figure 4b). Thus, although CDC5 overex-
pression is able to activate APC-mediated Clb2 proteolysis
in checkpoint-arrested cells, it does not allow cells to
escape from this arrest. 
Positive regulation of APC activity by Cdc5 requires kinase
activity 
We investigated whether APC regulation by Cdc5 is
dependent on Cdc5 kinase activity. Kinase-defective
mutants of Cdc5 were constructed by mutating lysine 110
to alanine (Cdc5-K110A) or asparagine 209 to alanine
(Cdc5-N209A) [56]. These mutants failed to complement
the cdc5-1 mutant (data not shown). In asynchronous pop-
ulations, overproduction of kinase-defective mutants
resulted in Cdc5 protein levels comparable to those of
wild-type Cdc5, but had no significant effect on APC
activity or Clb2 levels (Figure 6). 
In nocodazole-arrested cells, kinase-defective Cdc5
mutants displayed low levels of kinase activity and
induced minor increases in APC activity (Figure 6a,d),
resulting in similarly moderate decreases in Clb2. Interest-
ingly, the kinase activity of wild-type Cdc5 was also
higher in nocodazole-arrested cells, despite similar levels
of CDC5 expression from the GAL promoter (Figure 6d).
The correlation between kinase activity, APC activity and
Clb2 levels suggests that the kinase activity of Cdc5 is
required for the positive regulation of APC activity and
Clb2 proteolysis.
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Overproduction of Cdc5 results in increased APC-mediated Clb2
proteolysis. (a) A strain containing three copies of GAL–HA3–CDC5
(JC256), or a control strain lacking inducible CDC5 (AFS92), was
grown to early log phase in YEP/raffinose (lanes 1–4), or was arrested
in mitosis by treatment with 10 µg/ml nocodazole (Noc) after release
from an S phase arrest as described in Materials and methods (lanes
5,6). Equivalent strains (JC291, JC282) carrying the cdc13-1 (lanes
7,8) or cdc23-1 (lanes 9,10) mutations were arrested by shifting to the
non-permissive temperatures of 33°C or 37°C, respectively, for 3 h.
Galactose or dextrose was then added for 3 h to induce (+) or repress
(–) CDC5 expression, respectively, and cell lysates were prepared.
APC was immunoprecipitated from 200 µg cell extract with anti-
Cdc26 antibodies, and cyclin–ubiquitin ligase activity in vitro was
measured. The asterisk indicates a background band present in the
non-ubiquitinated substrate. (b) Cdc5 and (c) Clb2 protein levels were
analyzed as in Figure 3. (d) Cultures of cdc23-1 cells, with and without
inducible CDC5, were grown in YEP/raffinose to early log phase and
then arrested in mitosis by growth at 37° for 3 h. Galactose or
dextrose was added to 4% final concentration to induce (+) or repress
(–) CDC5 expression, respectively. Clb2-associated histone H1 kinase
activity (HH1) was measured in anti-Clb2 immunoprecipitates from
100 µg cell extract. (e) Cultures of strain JC260 (see Table 1) in
YEP/raffinose were arrested in 10 mg/ml hydroxyurea for 3 h and
released into 10 µg/ml nocodazole. After 2.5 h, 0.25 mM CuSO4 was
added to induce expression of the GFP–LacI fusion protein. After a
further 0.5 h, galactose (filled symbols) or dextrose (open symbols)
was added to 2% final concentration to induce or repress CDC5
expression, respectively. Sister-chromatid separation (triangles) was
then assessed by microscopic analysis of fluorescently-labeled lac
operator arrays on chromosome IV in 100 cells at the indicated times
after CDC5 induction or repression. Budding index (circles) was also
measured in 100 cells.
We also tested the effects of a Cdc5 mutant that is defec-
tive in the control of mitotic exit after DNA damage. Cells
arrested in mitosis by DNA damage eventually adapt to
the checkpoint arrest and exit mitosis in the presence of
damage, and mutation of leucine 251 in Cdc5 to trypto-
phan (Cdc5-L251W; cdc5-ad) causes defects in this adapta-
tion process, although normal cell-cycle progression is
unaffected [58]. Overproduction of Cdc5-L251W in asyn-
chronous cells resulted in an increase in APC activity and
a decrease in Clb2 levels comparable to those caused by
wild-type CDC5 (Figure 6). In nocodazole-arrested cells
(Figure 6d) and cdc13 mutant cells (data not shown), the
Cdc5-L251W mutant was significantly less effective in the
stimulation of APC activity than wild-type Cdc5, however,
even though it exhibited several-fold higher levels of
kinase activity (Figure 6d). Our results suggest that
cdc5-ad cells are unable to adapt to DNA damage due to a
defect in their ability to activate Clb2 proteolysis. As sug-
gested previously [58], it is possible that the Cdc5-L251W
mutant has normal catalytic activity but is defective in the
recognition of certain substrates. 
The effect of CDC5 overexpression is attenuated in hct1-D1
and cdc20-1 mutants
Like Cdc5, Hct1 is thought to be a specific activator of
APC-mediated Clb2 proteolysis [17,18]. It is therefore
possible that Cdc5 regulates the APC by a mechanism that
requires Hct1. On the other hand, the Hct1-related
protein Cdc20 does not appear to be required for Clb2
proteolysis in G1 [18,30], and therefore might not be
expected to play a role in the actions of Cdc5. 
We addressed this issue by assessing the effects of Cdc5
overproduction in hct1-∆1 and cdc20-1 mutants (Figure 7).
Cyclin ubiquitination by the APC in vitro was negligible in
hct1-∆1 cells (Figure 7a), and the stimulatory effects of
CDC5 expression on APC activity and Clb2 destruction
were greatly attenuated in the hct1-∆1 mutant, in both
asynchronous and nocodazole-arrested cultures
(Figure 7a,c). In multiple experiments, asynchronous
cdc20-1 cells growing at the permissive temperature in the
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Figure 6
The effect of CDC5 overexpression on APC activity requires Cdc5-
dependent kinase activity. Cells containing three integrated copies of
wild-type CDC5 (WT; JC256), CDC5-K110A (JC257), CDC5-N209A
(JC278), or CDC5-L251W (JC279) under the control of the GAL
promoter, or a control strain lacking inducible CDC5, were grown in
YEP/raffinose as asynchronous cultures or were arrested in mitosis by
treatment with 10 µg/ml nocodazole. Galactose or dextrose was then
added to 2% final concentration for 3 h to induce (+) or repress (–)
CDC5 expression, respectively. (a) APC activity was measured in anti-
Cdc26 immunoprecipitates from 200 µg cell extract. (b) Cdc5 and 
(c) Clb2 protein levels were analyzed as in Figure 3. (d) Cdc5-
dependent casein kinase activity was measured in 12CA5
immunoprecipitates of 400 µg cell extract.
Asynchronous Nocodazole
W
T
Co
ntr
ol
L2
51
W
K1
10
A
N2
09
A
W
T
L2
51
W
K1
10
A
N2
09
A
– + – + – + – + – + – + – + – + – +
GAL–CDC5
CDC5 
induction
APC activity
Cdc5
(a)
(b)
(c)
(d)
Clb2
Casein
*
Current Biology
Figure 7
The effects of CDC5 overexpression on APC activity require HCT1
and CDC20. Wild-type (W303), cdc20-1, or hct1-∆1 strains
containing three integrated copies of GAL–HA3–CDC5 (JC256, 272,
276) were grown in YEP/raffinose at 25°C as asynchronous cultures
or were arrested in mitosis by treatment with 10 µg/ml nocodazole.
Galactose or dextrose was then added for 3 h to induce (+) or repress
(–) CDC5 expression, respectively, and cell lysates were prepared. 
(a) APC activity was measured in anti-Cdc26 immunoprecipitates from
200 µg cell extract. The asterisk indicates a background band present
in the non-ubiquitinated substrate. (b) Cdc5 and (c) Clb2 protein
levels were analyzed as in Figure 3.
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absence of CDC5 overexpression displayed only slightly
decreased cyclin ubiquitination in our APC assay
(Figure 7a). The cdc20-1 mutation did reduce the stimula-
tory effects of Cdc5 overproduction on APC activity and
Clb2 proteolysis, however (Figure 7). We could not
examine the ability of CDC5 to activate Clb2 proteolysis in
cdc20-1 cells arrested in mitosis at the restrictive tempera-
ture, because we were unable to induce CDC5 expression
under these conditions. 
Our results suggest that Hct1 and Cdc20 both contribute
to the effect of Cdc5 on the cyclin ubiquitination activity
of the APC in vitro, despite previous indications that
Cdc20 is dispensable for Clb2 proteolysis. The relative
contributions of Hct1 and Cdc20 to Cdc5 function might
not be equivalent, however, as we found that the cdc5-1
hct1-∆1 double mutant is viable, whereas the cdc5-1 cdc20-1
double mutant is not (data not shown).
Cdc5 degradation in G1 is dependent on the APC and Hct1
Cdc5 protein levels closely parallel those of Clb2 through-
out the cell cycle, and decrease immediately after APC
activation (Figure 3). We have also observed that CDC5
induction from the GAL promoter in α-factor-arrested
cells, which contain fully active APC, results in less accu-
mulation of Cdc5 than that seen in asynchronous cells
(data not shown). Thus, we investigated the possibility
that Cdc5 stability in G1, like that of Clb2, is regulated by
the APC. We analyzed the stability of Cdc5 in α-factor-
arrested cells after transient induction of HA3–CDC5 from
the GAL promoter. Cdc5 was rapidly destroyed in wild-
type cells, with the bulk of Cdc5 protein disappearing
within 10 minutes of repression of transcription and trans-
lation by treatment with dextrose and cycloheximide,
respectively. In contrast, Cdc5 was stable in cdc23-1 cells,
confirming that Cdc5 degradation in G1 is dependent on
the APC. 
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Figure 8
Cdc5 degradation in G1 is dependent on the
APC and Hct1. (a) The stability of Cdc5 in
G1-arrested cells was examined by promoter
turn-off. Wild-type, cdc23-1, and cdc20-1
cells were grown in YEP/raffinose at 25°C,
arrested with 1 µg/ml α-factor until over 90%
of cells were in G1, and then shifted to 37°C
for 1 h. CDC5 was induced with 4%
galactose for 40 min, followed by addition of
dextrose (4%) and cycloheximide (10 µg/ml)
to repress transcription and translation,
respectively. Samples were taken at the
indicated times after repression, and extracts
were prepared in denaturing sample buffer.
HA-epitope-tagged Cdc5 was analyzed by
western blotting with 12CA5. As a loading
control, Cdc28 was detected on western
blots with anti-Cdc28 antibody. Cells
remained arrested in G1 for the duration of
the experiment. (b) Sequences of destruction
boxes from known APC substrates (Clb2,
Pds1 and Ase1) are aligned with the two
putative destruction boxes at arginines 17 and
60 of Cdc5 (Cdc5-db1 and Cdc5-db2,
respectively). Mutation of the indicated
arginines and leucines in both of these two
sequences resulted in the CDC5-db1,2
mutant. Cdc5 stability in cells containing
inducible wild-type CDC5 (JC256) or 
CDC5-db1,2 (JC309) was examined by
promoter turn-off as in (a), except that the
experiment was performed at 25°C, and sugar
concentrations were 2%. (c) Mutant cdc28-
13 HCT1 (JC310) and cdc28-13 hct1-∆1
(JC311) cells were arrested in G1 by growth
at 37°C for 3.5 h. Wild-type cells (JC256)
were arrested in G1 with 1 µg/ml α-factor and
shifted to 37°C for 1 h. In all cases, over 90%
of cells displayed G1 morphology throughout
the experiment. Cdc5 stability was measured
by promoter turn-off as in (a).
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All APC substrates identified so far contain sequences
known as destruction boxes, which were first identified in
B-type vertebrate cyclins [55,59]. Mutation of a conserved
arginine and leucine in the destruction box sequence pre-
vents APC-mediated destruction [37,59,60]. To confirm
that Cdc5 is an APC substrate, we also tested the effects
of mutations in putative destruction box sequences in
Cdc5. As the carboxy-terminal half of Cdc5 is completely
stable in G1 (data not shown), we focused on destruction
box sequences in the amino-terminal half of the protein.
Only two of these sequences lie outside conserved regions
of the kinase domain (Figure 8b). Mutation of conserved
residues in either of these two sequences had no effect on
Cdc5 stability in G1, but mutation of conserved residues
in both sequences (resulting in the Cdc5-db1,2 mutant)
caused partial Cdc5 stabilization (Figure 8b), suggesting
that Cdc5 is a direct APC substrate in G1. The residual
degradation of the Cdc5-db1,2 mutant is not observed in a
cdc23-1 mutant (data not shown), raising the possibility
that the APC recognizes additional destruction box
sequences in Cdc5. 
We also investigated whether Cdc5 degradation in G1 is
dependent on Hct1 or Cdc20. Like that of Clb2, the sta-
bility of Cdc5 in G1 was unaffected in the cdc20-1 mutant
at the restrictive temperature (Figure 8a). We also tested
the requirement for HCT1 in Cdc5 degradation. Because
hct1-∆1 mutants treated with α-factor re-replicate their
DNA and thus do not exhibit a normal G1 arrest [17], we
instead arrested cells in G1 with the cdc28-13 mutation
(APC activity in this mutant is comparable to that in α-
factor-arrested cells; S.L.J., unpublished observations). As
in α-factor-arrested cells, Cdc5 was quickly destroyed in
cdc28-13-arrested cells (Figure 8c). In cdc28-13 hct1-∆1
double mutants, however, Cdc5 was greatly stabilized. We
conclude that Cdc5 degradation in G1 is dependent on
both the APC and Hct1.
Discussion
Cdc5 is an activator of cyclin-specific APC activity
Our observations argue that Cdc5 is a key regulator of
APC activity and cyclin destruction. Decreased Cdc5
activity, as in the cdc5-1 mutant, results in decreased cyclin
ubiquitination by the APC in vitro, decreased cyclin
destruction in vivo, and increased sensitivity to cyclin
overexpression. Increased Cdc5 activity results in greater
APC activity and cyclin destruction.  
Cdc5 does not appear to stimulate APC activity towards all
substrates. Cells expressing the cdc5-1 mutant are defec-
tive in the destruction of cyclins but not that of Pds1; simi-
larly, CDC5 overexpression promotes cyclin destruction
but has relatively modest effects on the levels of Pds1.
These effects of Cdc5 are similar to those of Hct1: hct1-∆1
cells display a specific defect in cyclin destruction, and
HCT1 overexpression in asynchronous cells triggers the
destruction of cyclins but not Pds1. These findings, com-
bined with our observation that CDC5 overexpression has
little effect on APC activity in hct1-∆1 cells, suggest that
the actions of Cdc5 overlap with those of Hct1. Cdc5
might act upstream of Hct1 in the specific control of cyclin
destruction, or Hct1 may simply be an essential APC
subunit required for cyclin–ubiquitin ligase activity.
Although the functions of Cdc5 and Hct1 might overlap,
there are significant differences in the phenotypes of
CDC5 and HCT1 overexpression. Whereas HCT1 overex-
pression causes accumulation of G2 cells with elongated
buds [17], CDC5 overexpression is toxic but does not
cause a uniform cell-cycle arrest. Moreover, the toxicity of
CDC5 overexpression is not completely alleviated by
mutation of APC subunits (J.F.C., unpublished observa-
tions), whereas mutation of CDC23 allows growth of cells
overproducing HCT1 [17]. 
Despite previous evidence that Cdc20 is required primar-
ily for the destruction of Pds1 and not that of Clb2 [18],
we found that cdc20-1 mutants were defective in CDC5-
stimulated cyclin destruction. Thus, the substrate speci-
ficity of Cdc20 might overlap with that of Hct1 under
these conditions, as suggested by previous observations
that the overexpression of either HCT1 or CDC20 can
induce the destruction of both Pds1 and Clb2 in nocoda-
zole-arrested cells [18].
CDC5 overexpression in nocodazole-arrested cells does not
trigger separation of sister chromatids, presumably due to
its inability to induce Pds1 destruction. This seems incon-
sistent with previous work showing that chromosome sep-
aration can be achieved in nocodazole-arrested cells when
Sic1 is overproduced [33], suggesting that decreased
Cdc28–Clb activity can trigger Pds1 destruction. Unlike
our experiments, these studies of Sic1 overproduction
were performed in the presence of α-factor, which was
included to prevent the increase in G1 cyclin levels that
occurs when mitotic Clb levels decrease. Perhaps an
increase in G1 cyclin levels in our experiments prevented
the activation of APC activity toward Pds1, despite the
striking increase in APC activity toward cyclins. Alterna-
tively, CDC5 overexpression might not trigger the destruc-
tion of all mitotic cyclins, such that some Cdc28 activity
remains to suppress Pds1 destruction. 
Does Cdc5 have other functions in addition to the
promotion of cyclin destruction?
Our observation that Sic1 overexpression allows the cdc5-1
mutant to exit mitosis suggests that the key defect in this
mutant is an inability to inactivate Cdc28 in late mitosis.
Although our results suggest that this defect is due at least
in part to a reduction in cyclin-specific APC activity, it
remains possible that cdc5-1 cells are also defective in other
Cdc28 inactivation mechanisms, such as the production of
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Sic1. In hct1-∆1 cells, which exit mitosis despite a specific
defect in cyclin destruction, Sic1 has been implicated in
the inactivation of Cdc28 [17,18]. 
Previous work has shown that the cdc5-1 mutant has a
plasmid maintenance defect and is synthetically lethal
with orc2-1, a mutant in a subunit of the origin recognition
complex; in addition, there is evidence that Cdc5 interacts
with Dbf4, a protein implicated in the control of replica-
tion initiation [57]. Although these results could indicate a
direct role for Cdc5 in DNA replication, our results
provide an alternative explanation. The kinase activity of
mitotic Cdk–cyclin complexes is thought to prevent the
establishment of pre-replicative complexes, which are
required for the initiation of replication [61–63]. The high
levels of Clb2 in cdc5-1 mutant cells may interfere with the
normal timing of pre-replicative complex formation. 
Regulating the regulator: Cdc5 degradation
APC activity in cdc5-1 mutant cells is very low even at the
permissive temperature, resulting in an increased sensitiv-
ity to cyclin overexpression. Low APC activity is also seen
in cdc5-1 cells arrested in G1 by pheromone treatment,
presumably because full activation is not achieved in the
preceding mitosis. A shift of G1-arrested cdc5-1 cells to the
restrictive temperature does not cause a further significant
decrease in APC activity, however, suggesting that Cdc5 is
required for the initiation of APC activation in late mitosis,
but not for the maintenance of APC activity in G1. This
possibility is consistent with the low levels of Cdc5 protein
and Cdc5 activity in G1 cells, and with our observation
that Cdc5 is subject to APC-dependent degradation in G1.
These mechanisms might ensure that when the APC is
eventually inactivated at the end of G1, a key activator is
no longer present to initiate premature APC activation.
Material and methods
Plasmid and strain construction
All strains (Table 1) are derivatives of W303 MATa ade2-1, can1-100,
his3-11,15, leu2-3, trp1-1, ura3-1, ssd1-d, or backcrossed to W303 at
least four times. JC94 and JC95 are congenic strains derived by cross-
ing JC34 to W303 MATα ura3::GAL-CLB2-URA3 (gift of A. Rudner).
The 2µ CDC5 construct contained the CDC5 open reading frame plus
300 bp 5′ sequence and 500 bp 3′ sequence in pRS426. High-copy
SIC1 expression was achieved with pRS426 containing SIC1. In
strains JC243 and JC247, the PDS1 gene was replaced with a version
of the PDS1 gene encoding the Pds1 protein tagged at the carboxyl
terminus with a triple hemagglutinin (HA3) tag; this was generated by
the PCR epitope-tagging method of Schneider et al. [64]. In strain
JC35, CDC5 was replaced with a version of the gene that encoded an
amino-terminally HA3-epitope-tagged Cdc5 protein, and CDC27 was
replaced with a gene encoding Cdc27 tagged with MBP by a ‘pop-in,
pop-out’ strategy [65]. Strain JC251 was constructed by three copy
integration of pJC59, which contained a tagged version of the CDC5
gene (encoding Cdc5 tagged at the amino terminus with a triple Myc
epitope tag) under the control of the GAL1,10 promoter in pDK20
(kindly provided by D. Kellogg), at the ura3 locus of JC243. Southern
blot analysis with a 450 bp SalI–HpaI internal fragment of CDC5 was
used to identify a three-copy integration event. Similarly, strain JC256
contains three copies of pJC57, which is identical to pJC59 except
that an HA3 epitope tag replaces the Myc tag. Overexpression of
CDC5 in this strain results in Cdc5 protein levels being approximately
20–50-fold higher than the endogenous level observed in asynchro-
nous cells. Oligonucleotide-directed mutagenesis was used to intro-
duce the point mutations K110A, N209A and L251W into pJC57.
Strains JC257, JC278 and JC279 contain three copies of CDC5-
K110A, CDC5-N209A, or CDC5-L251W, respectively, integrated at
ura3 and identified by Southern analysis. Strains JC260, JC272,
JC276, JC282 and JC291 were derived from JC256 by crossing into
the desired background. W320 MATα hct1-∆1 was a gift of W.
Seufert [17]; SB213 MATα his3::CUP-GFP LacI-HIS3 trp1::LacO
was a gift of S. Biggins. Strain JC309 contains pJC88, containing
CDC5-db1,2 in which the mutations R17A, L20A, R60A, and L63A
were introduced by oligonucleotide-directed mutagenesis, integrated
at the ura3 locus. Strains JC310 and JC311 were derived by crossing
JC276 to MATα cdc28-13.
Yeast methods
Standard protocols for transformation, mating, sporulation, tetrad dis-
section, α-factor and hydroxyurea arrests were used [65]. For galac-
tose induction of epitope-tagged CDC5, cultures were grown to early
log phase in YEP/2% raffinose. Asynchronous cultures were induced
or repressed by the addition of 2% (final concentration) galactose or
dextrose, respectively, for 3 h. For galactose induction in nocodazole-
arrested cells, cultures were pre-arrested in 10 mg/ml hydroxyurea for
3 h, released into 10 µg/ml nocodazole for 2.5 h, after which galactose
was added (2%) in the continued presence of nocodazole (10 µg/ml).
For cell-cycle arrests plus induction, cultures were pre-arrested at the
non-permissive temperature for 3 h, followed by induction/repression
with 2% (33°C cultures) or 4% (37°C cultures) galactose/raffinose.
For sister-chromatid separation experiments, GFP-tagged sister chro-
matids were examined in 100 cells at each time point following the
method described in Straight et al. [57]. 
Protein analysis
Cell lysates were prepared by lysis with a BioSpec Beadbeater 8 in LLB
(50 mM Hepes-NaOH, pH 7.4, 75 mM KCl, 0.1% NP40, 5 mM NaF,
5 mM β-glycerophosphate, 1 mM MgCl2, 1 mM DTT) plus 1 mM PMSF
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Table 1
Yeast strains used in these studies.
Name Relevant genotype
JC34 MATa bar1 cdc5-1
JC94 MATa cdc5-1 ura3::GAL–CLB2–URA3
JC95 MATa ura3::GAL–CLB2–URA3
JC35 MATa bar1 cdc5::CDC5HA3 cdc27::CDC27MBP
AFS92 MATa bar1
JC256 MATa bar1 ura3::3X(GAL–CDC5HA3–URA3)
JC291 MATa cdc13-1 ura3::3X(GAL–CDC5HA3–URA3)
JC282 MATa cdc23-1 bar1 ura3::3X(GAL–CDC5HA3–URA3)
JC305 MATa cdc23-1
JC272 MATa cdc20-1 bar1 ura3::3X(GAL–CDC5HA3–URA3)
JC276 MATa hct1-∆1::LEU2 ura3::3X(GAL–CDC5HA3–URA3)
JC257 MATa ura3::3X(GAL–CDC5-K110AHA3–URA3)
JC278 MATa bar1 ura3::3X(GAL–CDC5-N209AHA3–URA3)
JC279 MATa ura3::3X(GAL–CDC5-L251WHA3–URA3)
JC260 MATa his3::CUP1–GFP–LacI–HIS3 trp1::LacO–TRP1
ura3::3X(GAL–CDC5HA3–URA3)
JC243 MATa pds1::PDS1HA3
JC251 MATa pds1::PDS1HA3 ura3::3X(GAL–CDC5MYC3–URA3)
JC247 MATa cdc5-1 pds1::PDS1HA3
JC309 MATa bar1 ura3::GAL–CDC5-db1,2HA3–URA3
JC310 MATa cdc28-13 ura3::3X(GAL–CDC5HA3–URA3)
JC311 MATa cdc28-13 hct1-∆1::LEU2 
ura3::3X(GAL–CDC5HA3–URA3)
and 1 µg/ml each of leupeptin, aprotinin and pepstatin. Clb2 western
blots and Clb2-associated kinase assays were performed as described
[66]. HA-epitope-tagged Cdc5 and HA-epitope-tagged Pds1 were
detected on western blots with mouse monoclonal antibodies 12CA5 or
16B12, respectively. HA3–Cdc5 kinase activity was measured in
12CA5 immunoprecipitates washed sequentially in LLB, high-salt QA
(20 mM Tris-HCl, pH 7.6, 250 mM KCl, 1 mM MgCl2, 1 mM DTT), and
5KB (50 mM Hepes-NaOH, pH 7.4, 200 mM KAc, 10 mM MgCl2, 5 mM
MnCl2, 1 mM DTT). Kinase assays (30 µl) were performed in 50 mM
Hepes-NaOH, pH 7.4, 60 mM KAc, 10 mM MgCl2, 5 mM MnCl2, 50 µM
ATP, plus 5 µg casein and 2.5 µCi [32P]ATP.
In vitro ubiquitination assay
The APC was immunoprecipitated with either polyclonal antibodies to
Cdc26 [27], the monoclonal antibody 12CA5 for strains containing a
plasmid bearing CDC16HA under its own promoter [67] or polyclonal
antibodies to MBP (New England BioLabs) for strains containing
CDC27–MBP replacing endogenous CDC27. Similar results were
obtained with all antibodies. After washing immunoprecipitates in LLB,
high salt QA, and QA (20 mM Tris-HCl, pH 7.6, 100 mM KCl, 1 mM
MgCl2, 1 mM DTT), ligase activity was measured by adding 15 µl reac-
tion mix containing 3.5 pmol Uba1, 47 pmol Ubc4, 1 nmol bovine ubiqui-
tin (Sigma), 1 mM ATP, and 0.25 µl 125I-labeled sea urchin cyclin B
(amino acids 12–91) [10,55]. After 15 min at 25°C, ubiquitin conju-
gates were resolved by electrophoresis on a 7.5–15% gradient gel and
visualized by autoradiography with the BioMaxMS system (Kodak).
Uba1–His6 was purified by metal-affinity chromatography from a yeast
strain expressing Uba1 under the control of the CUP1 promoter, kindly
provided by J. Dohmen. Ubc4 was purified from a bacterial expression
vector [68] following the protocol of H-F. Elin (personal communication). 
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